https://www.selleckchem.com/pr....oducts/bozitinib.htm
62; 95% confidence interval [CI] 0.56-0.68, p = less then 0.001) and 73% (OR = 0.27; 95% CI 0.18-0.41, p = less then 0.001) in HCQ recipients and non-recipients. These effects were maintained after adjusting for age, comorbidities, and diagnostic modality. No serious HCQ-related adverse drug reactions were reported. In our large outpatient national cohort of adults with mild COVID-19 disease who were given HCQ early in the course of the disease, the odds of hospitalization or death was reduced significantly regardless of age or comorb
Like
Comment
Share
